Published in Cancer Res on April 15, 1993
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev (2010) 3.77
Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A (1995) 3.25
Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci U S A (1994) 2.20
Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol (2005) 2.18
Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol (2004) 2.05
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol (2002) 2.02
Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol (2007) 1.90
Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol (2009) 1.79
The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol (2000) 1.73
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68
Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61
Astrocyte elevated gene-1 and c-Myc cooperate to promote hepatocarcinogenesis in mice. Hepatology (2015) 1.56
The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol Cell Biol (2005) 1.52
Nuclear receptor hepatocyte nuclear factor 4alpha1 competes with oncoprotein c-Myc for control of the p21/WAF1 promoter. Mol Endocrinol (2007) 1.40
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model. Hepatology (2012) 1.32
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology (2008) 1.29
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells. Cancer Res (2007) 1.21
Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha. Am J Pathol (1996) 1.14
Overexpression of transforming growth factor-alpha causes liver enlargement and increased hepatocyte proliferation in transgenic mice. Am J Pathol (1994) 1.13
Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer (2009) 1.12
Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver. Am J Pathol (1999) 1.09
Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review). Int J Oncol (2012) 1.05
Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model. Proc Natl Acad Sci U S A (2000) 1.04
Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. PLoS One (2008) 0.99
Experimental models of hepatocellular carcinoma: developments and evolution. J Cancer Res Clin Oncol (2009) 0.98
Mouse models in liver cancer research: a review of current literature. World J Gastroenterol (2008) 0.98
Acceleration of c-myc-induced hepatocarcinogenesis by Co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signaling disruption. Am J Pathol (1999) 0.96
Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci U S A (1996) 0.94
Role of Myc in hepatocellular proliferation and hepatocarcinogenesis. J Hepatol (2013) 0.92
Integrative oncogenomic approaches for accelerated cancer-gene discovery. Curr Opin Oncol (2008) 0.91
Pro-oncogenic potential of NM23-H2 in hepatocellular carcinoma. Exp Mol Med (2012) 0.91
In vivo MRS assessment of altered fatty acyl unsaturation in liver tumor formation of a TGF alpha/c-myc transgenic mouse model. J Lipid Res (2008) 0.90
Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus. J Cancer Res Clin Oncol (2006) 0.89
Non-mammalian fat-1 gene prevents neoplasia when introduced to a mouse hepatocarcinogenesis model: Omega-3 fatty acids prevent liver neoplasia. Biochim Biophys Acta (2010) 0.89
MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism. Cancer Res (2014) 0.88
Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Neoplasia (2012) 0.86
Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. Carcinogenesis (2011) 0.86
Selenium and selenoprotein deficiencies induce widespread pyogranuloma formation in mice, while high levels of dietary selenium decrease liver tumor size driven by TGFα. PLoS One (2013) 0.81
Xylosyltransferase II is a significant contributor of circulating xylosyltransferase levels and platelets constitute an important source of xylosyltransferase in serum. Glycobiology (2009) 0.81
FOXN3 Regulates Hepatic Glucose Utilization. Cell Rep (2016) 0.80
Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model. Oncotarget (2015) 0.79
Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma. PLoS One (2011) 0.79
Synergistic Induction of Potential Warburg Effect in Zebrafish Hepatocellular Carcinoma by Co-Transgenic Expression of Myc and xmrk Oncogenes. PLoS One (2015) 0.78
The role of AEG-1 in the development of liver cancer. Hepat Oncol (2016) 0.78
Integrative Functional Genomics Implicates EPB41 Dysregulation in Hepatocellular Carcinoma Risk. Am J Hum Genet (2016) 0.78
TGF-β1 and TGF-β2 abundance in liver diseases of mice and men. Oncotarget (2016) 0.78
Recurrent and nonrandom DNA copy number and chromosome alterations in Myc transgenic mouse model for hepatocellular carcinogenesis: implications for human disease. Cancer Genet Cytogenet (2009) 0.77
SGF29 and Sry pathway in hepatocarcinogenesis. World J Biol Chem (2015) 0.77
Mouse models of liver cancer: Progress and recommendations. Oncotarget (2015) 0.77
Integrative genomics: liver regeneration and hepatocellular carcinoma. J Cell Biochem (2012) 0.77
Regulatory functions of Nm23-H2 in tumorigenesis: insights from biochemical to clinical perspectives. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75
Endogenous antibodies for tumor detection. Sci Rep (2014) 0.75
Gadoxetate acid-enhanced MRI of hepatocellular carcinoma in a c-myc/TGFα transgenic mouse model including signal intensity and fat content: initial experience. Cancer Imaging (2012) 0.75
Development of murine models to study Hepatitis C virus induced liver pathogenesis. Indian J Virol (2013) 0.75
Enhanced angiogenesis, hypoxia and neutrophil recruitment during Myc-induced liver tumorigenesis in zebrafish. Sci Rep (2016) 0.75
c-MYC-Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease. Genes (Basel) (2017) 0.75
Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers. Gastroenterology Res (2009) 0.75
c-Myc and transforming growth factor α enhance the development of hepatic lesions due to mutant β-catenin in transgenic mice. Comp Med (2014) 0.75
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene (2009) 3.51
Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A (1995) 3.25
A precursor-product relationship exists between oval cells and hepatocytes in rat liver. Carcinogenesis (1987) 2.98
Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet (1992) 2.63
Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther (1974) 2.62
Cellular distribution of transforming growth factor-beta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest (1990) 2.61
Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev (1992) 2.59
Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res (1998) 2.59
In vivo differentiation of rat liver oval cells into hepatocytes. Cancer Res (1989) 2.58
Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest (1996) 2.42
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene (2012) 2.41
Neonatal sunburn and melanoma in mice. Nature (2001) 2.25
Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci U S A (1994) 2.20
Dynamic, yet structured: The cell membrane three decades after the Singer-Nicolson model. Proc Natl Acad Sci U S A (2003) 2.20
Atypical ductular proliferation and its inhibition by transforming growth factor beta1 in the 3,5-diethoxycarbonyl-1,4-dihydrocollidine mouse model for chronic alcoholic liver disease. Lab Invest (1999) 2.16
Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A (1997) 2.12
Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J (1998) 2.07
Origin and structural evolution of the early proliferating oval cells in rat liver. Am J Pathol (2001) 2.07
Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res (1994) 2.06
Expression of stem cell factor and its receptor, c-kit, during liver regeneration from putative stem cells in adult rat. Lab Invest (1994) 1.90
Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res (1996) 1.90
Targeting expression of a transforming growth factor beta 1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J (1993) 1.86
Dose-dependent enzyme induction. Clin Pharmacol Ther (1973) 1.84
Expression of hepatic transcription factors during liver development and oval cell differentiation. J Cell Biol (1994) 1.80
Comparative and integrative functional genomics of HCC. Oncogene (2006) 1.75
Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target. Proc Natl Acad Sci U S A (1996) 1.73
The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol (2000) 1.73
Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. Pharmacology (1974) 1.70
Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts. Eur J Immunol (2001) 1.68
Malignant melanoma: modern black plague and genetic black box. Genes Dev (1998) 1.67
Origin and fate of oval cells in dipin-induced hepatocarcinogenesis in the mouse. Am J Pathol (1994) 1.67
Renal cysts in transgenic mice expressing transforming growth factor-alpha. J Lab Clin Med (1994) 1.66
Changes in liver blood flow during enzyme induction. Biochem Pharmacol (1971) 1.65
Interindividual differences in rates of drug oxidation in man. Drug Metab Dispos (1974) 1.63
Expression of acidic fibroblast growth factor in regenerating liver and during hepatic differentiation. Lab Invest (1992) 1.63
Constitutive expression of a truncated INT3 gene in mouse mammary epithelium impairs differentiation and functional development. Cell Growth Differ (1995) 1.62
Smoking and industrial pollution, and their effects on menopause and ovarian cancer. Lancet (1978) 1.59
Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology (2000) 1.59
Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. Hepatology (1992) 1.58
The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci U S A (1996) 1.56
Ectopic TGF beta 1 expression in the secretory mammary epithelium induces early senescence of the epithelial stem cell population. Dev Biol (1995) 1.56
DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus. Nat Genet (1997) 1.55
c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res (1998) 1.54
Left ventricular diastolic and systolic function in normotensive obese subjects: influence of degree and duration of obesity. Eur Heart J (1992) 1.52
Novel recurrent genetic imbalances in human hepatocellular carcinoma cell lines identified by comparative genomic hybridization. Hepatology (1999) 1.50
Are there any predictive factors for successful testicular sperm recovery in azoospermic patients? Hum Reprod (1997) 1.48
Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene (2008) 1.48
Wholesale hepatocytic differentiation in the rat from ductular oval cells, the progeny of biliary stem cells. J Hepatol (1997) 1.47
Differential effects of transforming growth factor-beta on proliferation of normal and malignant rat liver epithelial cells in culture. Cancer Res (1986) 1.43
Imaging molecular interactions in cells by dynamic and static fluorescence anisotropy (rFLIM and emFRET). Biochem Soc Trans (2003) 1.43
Acetaminophen-induced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. Pharmacology (1974) 1.43
Intrapleural streptokinase in the treatment of haemothorax and empyema. Scand J Thorac Cardiovasc Surg (1977) 1.43
Expression of cellular myc and mos genes in undifferentiated B cell lymphomas of Burkitt and non-Burkitt types. Proc Natl Acad Sci U S A (1983) 1.42
Substance abuse treatment. Beyond the Minnesota model. N C Med J (1994) 1.39
[Neurofibromatosis (von Recklinghausen disease) and carcinoid tumor in Vater's ampulla]. Orv Hetil (1995) 1.39
Activation of hepatic stem cell compartment in the rat: role of transforming growth factor alpha, hepatocyte growth factor, and acidic fibroblast growth factor in early proliferation. Cell Growth Differ (1993) 1.38
[Comparative analysis of diagnoses by the referring family physician and the hospital admission committee in ambulatory patients at an internal medicine department]. Orv Hetil (1997) 1.38
Cytological changes in the pancreas of transgenic mice overexpressing transforming growth factor alpha. Gastroenterology (1992) 1.36
Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ (1996) 1.36
Partial cloning of rat CD34 cDNA and expression during stem cell-dependent liver regeneration in the adult rat. Hepatology (1997) 1.34
Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene (2000) 1.33
Oval cell differentiation into hepatocytes in the acetylaminofluorene-treated regenerating rat liver. Hepatology (1995) 1.33
Precursor-product relationship between oval cells and hepatocytes: comparison between tritiated thymidine and bromodeoxyuridine as tracers. Carcinogenesis (1996) 1.29
Expression of hepatocyte growth factor and c-met genes during hepatic differentiation and liver development in the rat. Am J Pathol (1993) 1.28
Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science (1987) 1.28
The Ah locus and the metabolism of chemical carcinogens and other foreign compounds. Adv Cancer Res (1977) 1.27
Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development. Proc Natl Acad Sci U S A (1996) 1.27
Involvement of hepatocyte growth factor/scatter factor and met receptor signaling in hair follicle morphogenesis and cycling. FASEB J (2000) 1.26
Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res (1998) 1.23
Modulation of keratin 14 and alpha-fetoprotein expression during hepatic oval cell proliferation and liver regeneration. J Cell Physiol (1994) 1.22
Transforming growth factor-beta 1 and type I procollagen transcripts during regeneration and early fibrosis of rat liver. Lab Invest (1990) 1.22
Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res (2001) 1.22
Sequential activation of murine mononuclear phagocytes for tumor cytolysis: differential expression of markers by macrophages in the several stages of development. J Immunol (1983) 1.22
Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Mol Cell Biol (2000) 1.21
Contribution of CYLN2 and GTF2IRD1 to neurological and cognitive symptoms in Williams Syndrome. Neurobiol Dis (2006) 1.21
Hypertrophic gastropathy resembling Ménétrier's disease in transgenic mice overexpressing transforming growth factor alpha in the stomach. J Clin Invest (1992) 1.20
Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man. Ann N Y Acad Sci (1971) 1.20
NANOG modulates stemness in human colorectal cancer. Oncogene (2012) 1.19
Reduced growth capacity of hepatocytes from c-myc and c-myc/TGF-alpha transgenic mice in primary culture. Biochem Biophys Res Commun (1996) 1.18
Carcinogenicity of 2-amino-3-methylimidazo[4,5-f]quinoline in nonhuman primates: induction of tumors in three macaques. Jpn J Cancer Res (1990) 1.16
Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res (1997) 1.16
Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol (2010) 1.16
In vivo infusion of growth factors enhances the mitogenic response of rat hepatic ductal (oval) cells after administration of 2-acetylaminofluorene. Hepatology (1996) 1.14
Transforming growth factor alpha disrupts the normal program of cellular differentiation in the gastric mucosa of transgenic mice. Development (1995) 1.14
Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha. Am J Pathol (1996) 1.14
Overexpression of transforming growth factor-alpha causes liver enlargement and increased hepatocyte proliferation in transgenic mice. Am J Pathol (1994) 1.13
Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. Oncogene (2010) 1.13
Interaction of Bacillus Calmette--Guérin-activated macrophages and neoplastic cells in vitro II. The relationship of selective binding to cytolysis. Cell Immunol (1980) 1.13
Exocrine pancreatic disorders in transsgenic mice expressing human keratin 8. J Clin Invest (1999) 1.11
Autonomous growth in serum-free medium and production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor alpha 1. Cancer Res (1994) 1.11